The Potentially Deadly Mistake People Make When Returning From Vacation

Whether you're walking around Disney World, swimming in the ocean or taking a mountain trip, it's needless to say that many vacations — while tons of fun — can also be tiresome. After packing in as much as possible on your days off, exhaustion may set in as you rush back home to prepare for going back to work or school.
It's important to be aware of a danger that comes with this: drowsy driving. Defined as driving while sleepy, it's more common than you think. According to a Centers for Disease Control survey, about 1 in 25 adult drivers reported falling asleep while driving within the past 30 days.
According to a study by the AAA Foundation for Traffic Safety, 21% of fatal crashes involved a drowsy driver. So, while you may feel like you're in control and can keep yourself awake, remember that probably everyone in that situation also felt the same.
Tiredness can affect your mind and ability to drive in a slew of ways, too, so there's no one way in which an accident will happen. According to Susan Miller, a lead researcher and certified sleep expert at SleepMattressHQ.com, being sleepy can impair your judgment and decision-making, reduce awareness of your surroundings (from cars to road conditions to traffic signals), and affect your coordination, balance and fine motor skills.
'Even a momentary lapse of attention can be dangerous while driving, so prioritizing safety is important,' she added.
Jeff Kahn, a sleep expert and the CEO and co-founder of Rise Science, agreed. 'Microsleeps, in particular, are a cause for alarm, as they can last only a few seconds and occur unknowingly,' he said. 'While this might not seem like much, on a highway traveling at 65 miles per hour, those seconds can mean the difference between life and death.'
Further, the dangers of driving while sleepy are often compared to the dangers of driving drunk. Kahn said 24 hours worth of sleep deprivation — at once, or accumulated over time — results in the same cognitive impairment equivalent as a blood alcohol content (BAC) of 0.10%, which is higher than the legal limit. And again, he added, it's unsafe to drive even before you reach that point.
He pointed to the concept of 'sleep debt,' or not getting enough sleep cumulatively. 'If you regularly miss an hour of sleep for 10 consecutive nights, your cognitive impairment can be as severe as if you hadn't slept for 24 hours straight,' he explained.
One of the two time ranges when this occurs may surprise you. According to the Department of Health of New York State, most sleep-related crashes occur between 1 p.m. and 4 p.m., and 2 a.m. and 6 a.m. So yes, driving in the early morning isn't a great idea, but that 'afternoon slump' period isn't either.
This is when bodies are typically the most tired. 'Importantly, these are the times when you're biologically-inclined to be more drowsy, thanks to the peaks and dips of your circadian rhythm (your internal body clock),' Kahn said. 'Your circadian energy dips will happen regardless if you had enough sleep or not, but sleep deprivation will make you feel drowsier at these times than you otherwise would.'
Unfortunately, many factors can contribute to this, though some may be more common than others. Here are a few of the most common ones:
'One of the biggest contributors to drowsy driving is sleep deprivation,' Miller said. 'This can lead to difficulty concentrating, slower reaction times and even falling asleep at the wheel.'
While the amount of sleep each person needs will vary, most adults need seven to nine hours a night, she added. (BTW, 'junk sleep,' or low-quality sleep, doesn't count.)
A bigger sleeping issue may be going on, so checking with a doctor is smart. 'Some disorders, like obstructive sleep apnea, cause low-quality sleep as sleep is often interrupted or restricted, thus low-quality and less restorative,' said Nicole Eichelberger, a sleep expert at Mattressive.
What's even scarier is that it's not always noticeable. 'Unfortunately, most people who suffer from sleep disorders are unaware,' she continued. 'Therefore, it is essential to seek medical help if you notice excessive daytime sleepiness.'
Miller also listed alcohol and medications, such as antihistamines or benzodiazepines, as contributors to drowsiness and impaired cognitive function. So if you're enjoying a few cocktails by the pool, for example, be cognizant of this.
'Even small amounts of alcohol and certain drugs can cause drowsiness, poor coordination and slower reaction times, making driving dangerous,' she said. To avoid this, Eichelberger urged reading the side effects listed on the medicines you take, and to avoid driving if drowsiness is listed.
The time of day and distance matter, too. Many of us road trip to our vacation destinations and often power through the drive in order to get there or get home.
'Driving overnight (which can be tempting to avoid traffic) increases the risk of experiencing sleepiness, even if you think you are well-rested,' said Holly Milling, a clinical psychologist, behavioral sleep medicine specialist and director of The Sleep Practice. 'Driving for long periods of time, at any time of day, is also tiring, and driving without a break can increase vulnerability to sleepiness.'
Simply put, you shouldn't drive while sleepy, even if you think you can make yourself stay awake. More specifically, here are some other danger signs these experts listed:
Being unable to remember driving for the last few minutes
Struggling to focus your eyes and concentrate
Drifting into another lane
Head bobbing
Yawning
Feeling easily frustrated
Rubbing your eyes or struggling to keep them open
Following cars too closely
Getting restless or fidgeting
Not keeping a consistent speed
Braking too late
Missing signs and exits
'Even if you don't feel like you'll fall asleep, these signs indicate that your driving ability is impaired and that it's unsafe to continue driving,' Kahn said.
As tempting as it sounds, the answer isn't louder music, colder air or talking to someone. 'The only cure for sleepiness is sleep,' Milling said.
While napping in public may feel uncomfortable, it's crucial. You can take a nap at a rest area, gas station or other place you feel safe. And hey, only a short nap is needed.
'Ideally, you should take a 20 to 30 minute nap to feel refreshed, but not so long that you enter a deep sleep cycle and wake up feeling groggy,' Miller said. 'If you're unable to nap, simply resting your eyes or having a break from driving for a few minutes can also be helpful.'
While caffeine can help, Miller continued, it's a short-term fix and it can't cure severe fatigue. She recommends drinking about 200mg of caffeine (equivalent to a cup of coffee) 30 minutes before getting back on the road.
Having a coffee between napping and driving also adds time between waking up and driving, which Kahn said is important. He encourages having that buffer time 'to ensure the post-nap grogginess doesn't affect your driving skills (even if you've only napped for less than 20 minutes).'
Combining the two can eliminate mid-afternoon sleepiness for up to an hour, according to a study in the journal Psychophysiology. But again, these experts say a nap comes first and foremost. 'Whether you include caffeine or not, though, the most important ingredient is the nap,' Milling emphasized. 'Never skip sleep in favor of a double espresso.'
Lastly, while it may seem counterintuitive, some movement (along with the nap) can help. 'A short burst of exercise can wake you up and increase your alertness,' Miller said. She encouraged light stretching or a short walk. You could even get some errands done during this time, like walking around the grocery store.
If these options feel undoable or aren't cutting it, don't let that deter you. 'Call someone to drive you home or the rest of the way,' Eichelberger urged. 'You can also find a motel [and] rest for the night, or get a cab and head home.'While a Lyft ride or motel stay won't be inexpensive, it is cheaper — and safer — than the alternative.
Long-term, Eichelberger recommended maintaining good sleep habits. If you notice excessive fatigue often, she added, consider talking to a sleep doctor so you can avoid car accidents (and various other problems).
Being proactive is always smart, too. Milling mentioned not driving if you've been awake for 18+ hours and scheduling breaks every couple of hours, to start. This way, you're less likely to get caught in a drowsy driving situation.
While vacations and life can keep us busy, sacrificing sleep isn't a great idea — especially if you're ever behind the wheel.
The Time It Takes To Fall Asleep Can Reveal A Lot About Your Health
How To Change Your Default Sleeping Position To A New One
The 1 Habit Doctors Say Is Secretly Making You Tired The Next Day

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Medscape

27 minutes ago

• Medscape

Fewer ECG Abnormalities in Early T2D With Combo Therapy

TOPLINE: In patients with type 2 diabetes (T2D) of less than 10 years' duration who were taking metformin monotherapy, ECG abnormalities — including evidence of cardiovascular autonomic neuropathy — were common and associated with cardiovascular risk factors. After adding one of four frequently used glucose-lowering agents to metformin, fewer major ECG changes occurred with liraglutide than with the other treatments. METHODOLOGY: Researchers aimed to examine ECG abnormalities and cardiovascular autonomic neuropathy across the different glucose-lowering treatment groups in 5029 participants (mean age, 57.2 years; diabetes duration, 4.2 years; A1c level, 7.5%; 36.4% women) from the GRADE trial. The participants had T2D for less than 10 years and were initially taking metformin monotherapy before being randomly assigned to receive metformin plus one of four commonly used glucose-lowering agents (insulin glargine, glimepiride, liraglutide, or sitagliptin). Patients were followed up for an average of 5 years. Resting ECGs were recorded at baseline and at 2‐ and 4‐year follow-ups and analyzed for overall, major, and minor abnormalities, as well as heart rate variability — a measure of cardiovascular autonomic neuropathy. TAKEAWAY: More than half of participants in the GRADE trial had ECG abnormalities (57.1%) and ECG-defined cardiovascular autonomic neuropathy (52.8%) at baseline. The presence of these abnormalities was associated with longer diabetes duration, higher systolic blood pressure, greater prevalence of hyperlipidemia, more frequent use of lipid-lowering treatment, and beta-blocker use. Major ECG abnormalities occurred less frequently in the liraglutide group than in the other treatment groups (9% vs 13% at 4 years). Researchers found no significant differences in ECG-defined cardiovascular autonomic neuropathy between the liraglutide and non-liraglutide groups at 2 and 4 years (P = .42). IN PRACTICE: "ECG abnormalities, including those of CAN [cardiovascular autonomic neuropathy], are common in T2D < 10 years and are associated with certain CV [cardiovascular] risk factors. The development of major ECG abnormalities may differ by glucose-lowering treatment, as fewer occurred with liraglutide vs the other treatments," the authors concluded. SOURCE: The study was led by Rodica Pop-Busui, MD, PhD, Oregon Health & Science University in Portland. The results were presented on June 20 at the American Diabetes Association (ADA) 85th Scientific Sessions, being held June 20-23 at the McCormick Place Convention Center in Chicago, Illinois. LIMITATIONS: This abstract did not discuss any limitations. DISCLOSURES: Some authors disclosed receiving research support, consulting fees; serving on boards, advisory panels; being stock/shareholders; or other relationships with pharmaceutical and diagnostics companies and institutions. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Yahoo

41 minutes ago

• Yahoo

Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials

Results from the fixed-dose QWINT-1 study, along with the QWINT-3 and QWINT-4 studies, reinforce efsitora's potential to simplify insulin management with weekly dosing Lilly plans to submit efsitora for the treatment of adults with type 2 diabetes to global regulatory agencies by the end of this year INDIANAPOLIS, June 22, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from QWINT-1, QWINT-3, and QWINT-4 Phase 3 clinical trials evaluating the safety and efficacy of investigational once-weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes who used insulin for the first time, previously used daily basal insulin, and previously used daily basal insulin and mealtime insulin, respectively. In each trial, once-weekly efsitora met the primary endpoint of non-inferior A1C reduction compared to daily basal insulin. The complete results from these studies were presented at the American Diabetes Association (ADA) 85th Scientific Sessions 2025. Simultaneously, results from QWINT-1, a first-of-its-kind fixed-dose study, were published in The New England Journal of Medicine, while results from QWINT-3 and QWINT-4 were published in The Lancet. In QWINT-1, efsitora reduced A1C by 1.31% compared to 1.27% for insulin glargine at week 52 for the efficacy estimand.1,2 In the trial, efsitora was titrated to four fixed doses at four-week intervals, as needed for blood glucose control.3 In QWINT-3, efsitora reduced A1C by 0.86% compared to 0.75% for insulin degludec at week 26 for the efficacy estimand.4 In QWINT-4, efsitora reduced A1C by 1.07% compared to 1.07% for insulin glargine at week 26 for the efficacy estimand.5 In these two trials, efsitora was administered using traditional insulin dosing with adjustments based on each patient's glucose level. "The novel fixed-dose regimen used in QWINT-1 for once-weekly efsitora, which consisted of only four single-dose titration options, has the potential to facilitate and simplify insulin therapy, reducing the hesitation often associated with starting insulin to treat type 2 diabetes," said Dr. Julio Rosenstock, senior scientific advisor for Velocity Clinical Research at Medical City Dallas, clinical professor of medicine, University of Texas Southwestern Medical Center, and lead trial investigator for QWINT-1. "A simpler, once-weekly regimen with efsitora may help people with type 2 diabetes initiate and manage insulin therapy with the goal of improving blood sugar levels. Across all QWINT trials, the results showed that once-weekly efsitora controlled glucose as effectively as the most popular once-daily basal insulins." QWINT-1 Primary EndpointEfficacy Estimand Treatment-RegimenEstimand6 Primary Endpoint – A1C Reduction (Resulting A1C) at Week 52 Efsitora -1.31 % (6.92 %) -1.19 % (7.05 %) Glargine -1.27 % (6.96 %) -1.16 % (7.08 %)QWINT-3 Primary and Key Secondary EndpointsEfficacy Estimand Treatment-RegimenEstimand Primary Endpoint – A1C Reduction (Resulting A1C) at Week 26 Efsitora -0.86 % (6.93 %) -0.81 % (6.99 %) Degludec -0.75 % (7.03 %) -0.72 % (7.08 %) Key Secondary Endpoint – Rates of Clinically Significant or Severe Nocturnal Hypoglycemic Events Per Patient-Year of Exposure up to Week 787,8 Efsitora 0.11 Degludec 0.10 Key Secondary Endpoint – Percent Time in Range (70-180 mg/dL) During the FourWeeks Prior to Week 26 Efsitora 62.8 % 61.4 % Degludec 61.3 % 61.0 %QWINT-4 Primary and Key Secondary EndpointsEfficacy Estimand Treatment-Regimen Estimand Primary Endpoint – A1C Reduction (Resulting A1C) at Week 26 Efsitora -1.07 % (7.12 %) -1.01 % (7.17 %) Glargine -1.07 % (7.11 %) -1.00 % (7.18 %) Key Secondary Endpoint – Participants Achieving A1C <7% at Week 26 Without Nocturnal Hypoglycemia Efsitora 39.5 % 38.6 % Glargine 36.6 % 35.9 % Key Secondary Endpoint – Rates of Clinically Significant or Severe NocturnalHypoglycemic Events Per Patient-Year of Exposure up to Week 26 Efsitora 0.67 Glargine 1.00 "Building on Lilly's legacy of innovation in insulin therapy, once-weekly efsitora may offer a significant advancement for people with type 2 diabetes who need insulin by eliminating over 300 injections per year," said Jeff Emmick, M.D., Ph.D., senior vice president of product development at Lilly. "These results reinforce the potential for once-weekly efsitora to help reduce the overall burden of insulin therapy through a simplified treatment approach. We look forward to working with regulatory agencies to bring this innovation to patients around the world." Across the three trials, efsitora demonstrated an overall safety profile similar to two of the most commonly used daily basal insulin therapies for the treatment of type 2 diabetes. In QWINT-1, efsitora resulted in approximately 40% fewer hypoglycemic events compared to insulin glargine, with estimated combined rates of severe or clinically significant hypoglycemic events per patient-year of exposure of 0.50 with efsitora vs. 0.88 with insulin glargine at 52 weeks. In QWINT-3, these rates were 0.84 with efsitora vs. 0.74 with insulin degludec at 78 weeks. In QWINT-4, estimated combined rates of severe or clinically significant hypoglycemic events per patient-year of exposure were 6.6 with efsitora vs. 5.9 with insulin glargine at 26 weeks. Lilly plans to submit efsitora for the treatment of adults with type 2 diabetes to global regulatory agencies by the end of this year. About the QWINT clinical trial programThe QWINT Phase 3 global clinical development program for insulin efsitora alfa (efsitora) in diabetes began in 2022 and has enrolled more than 3,000 people living with type 2 diabetes across four global registration studies. QWINT-1 (NCT05662332) was a parallel-design, open-label, treat-to-target, randomized controlled clinical trial comparing the efficacy and safety of efsitora as a once-weekly basal insulin using a fixed dose escalation to daily insulin glargine for 52 weeks in insulin-naïve adults with type 2 diabetes. The trial randomized 795 participants across the U.S., Argentina and Mexico to receive efsitora once weekly or insulin glargine once daily, administered subcutaneously. Participants treated with efsitora received a starting dose of 100 units of insulin, followed by escalation to fixed dosages of 150 units, 250 units and 400 units every four weeks, as needed, until achieving a target fasting blood glucose of 80-130 mg/dL. Participants with fasting blood glucose greater than 130 mg/dL on or after 16 weeks were transferred to flexible dosing. The primary objective of the trial was to demonstrate non-inferiority in reducing A1C at week 52 with efsitora compared to daily use of insulin glargine. QWINT-3 (NCT05275400) was a multicenter, randomized, parallel-design, open-label trial comparing the efficacy and safety of efsitora as a once-weekly basal insulin to insulin degludec for 78 weeks after a three-week lead-in followed by a five-week safety follow up period, in adults with type 2 diabetes who are currently treated with basal insulin. The trial randomized 986 participants across the U.S., Argentina, Hungary, Japan, Korea, Poland, Puerto Rico, Slovakia, Spain and Taiwan to receive efsitora once weekly or insulin degludec once daily, administered subcutaneously. The primary objective of the study was to demonstrate non-inferiority in reducing A1C at week 26 with efsitora compared to insulin degludec. QWINT-4 (NCT05462756) was a parallel-design, open-label, treat-to-target, randomized controlled clinical trial comparing the efficacy and safety of efsitora as a weekly basal insulin to insulin glargine for 26 weeks in adults with type 2 diabetes who have previously been treated with basal insulin and at least two injections per day of mealtime insulin. The trial randomized 730 participants across the U.S., Argentina, Germany, India, Italy, Mexico, Puerto Rico and Spain to receive efsitora once weekly or insulin glargine once daily, both of which were administered subcutaneously along with insulin lispro. The primary objective of the trial was to demonstrate non-inferiority in reducing A1C at week 26 with efsitora compared to insulin glargine. About insulin efsitora alfaInsulin efsitora alfa (efsitora) is a once-weekly basal insulin, a fusion protein that combines a novel single-chain variant of insulin with a human IgG2 Fc domain. It is specifically designed for once-weekly subcutaneous administration, and with its low peak-to-trough ratio, it has the potential to provide more stable glucose levels (less glucose variability) throughout the week. About Lilly Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit and or follow us on Facebook, Instagram, and LinkedIn. P-LLY The efficacy estimand represents the treatment effect on all participants who adhered to the study drug without initiating rescue therapy for persistent severe hyperglycemia. From a baseline of 8.20% for efsitora and 8.28% for insulin glargine. Participants treated with efsitora received a starting dose of 100 units of insulin, followed by escalation to fixed dosages of 150 units, 250 units and 400 units every four weeks, as needed, until achieving a target fasting blood glucose of 80-130 mg/dL. Participants with fasting blood glucose greater than 130 mg/dL on or after 16 weeks were transferred to flexible dosing. From a baseline of 7.80% for both efsitora and insulin degludec. From a baseline of 8.18% for both efsitora and insulin glargine. The treatment-regimen estimand represents the estimated average treatment effect regardless of treatment discontinuation or introduction of rescue therapy for persistent severe hyperglycemia. Blood glucose <54 mg/dL. Nocturnal hypoglycemia was defined as any event that occurred at night between midnight and 6 a.m. Cautionary Statement Regarding Forward-Looking StatementsThis press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about insulin efsitora alfa as a potential treatment for people with type 2 diabetes and the timeline for future readouts, presentations, and other milestones relating to insulin efsitora alfa and its clinical trials and reflects Lilly's current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development, and commercialization. Among other things, there is no guarantee that future study results will be consistent with study results to date, that insulin efsitora alfa will prove to be a safe and effective treatment for type 2 diabetes, that insulin efsitora alfa will receive regulatory approval, or that Lilly will execute its strategy as expected. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release. Trademarks and Trade NamesAll trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are referenced in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies. Refer to: Niki Biro; niki_biro@ 317-358-9074 (Media)Michael Czapar; czapar_michael_c@ 317-617-0983 (Investors) View original content to download multimedia: SOURCE Eli Lilly and Company Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

CBS News

an hour ago

• CBS News

Annual Fight For Air Climb at Soldier Field raises over $350K for lung health

Despite the heat in Chicago, climbers took to Soldier Field for the annual Fight For Air Climb event to raise thousands of dollars for lung health. Over 700 people from different skill levels participated in Sunday morning's event, presented by UnitedHealthcare, to raise money for research, education, and advocacy. In the end, they raised over $350,000. The climb helps support the over 1.4 million people living with lung disease in Illinois. Due to the weekend's dangerous weather, organizers had changed the original 1,600-step route and added portable misting fans. The heat, however, didn't stop the Firefighter Challenge as teams of firefighters climbed in full gear. The American Lung Association said it looks forward to next year's event and "continuing its commitment to improving lung health and preventing lung disease."